San Diego Firm Expands Cancer Treatment Trials
Rakuten Medical advances Phase 3 clinical trials for its photoimmunotherapy platform.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Would you prefer a less invasive light-based cancer treatment over traditional surgery if offered one?
San Diego-based Rakuten Medical is conducting Phase 3 clinical trials in the United States for its light-activated cancer treatment. The company, which is profitable in Japan, aims to expand its reach globally while preparing for an FDA submission in 2028.
Why it matters
The firm targets the U.S. market because it represents the largest area for capital deployment. By expanding into regions like Macau, the company seeks to build population data for future commercialization in China.
Rakuten Medical currently treats 700 to 800 patients annually across 200 hospitals in Japan using its Alluminox platform. The company allocates 95% of its resources to the U.S. market to support its clinical development efforts.
The players
Rakuten Medical
This San Diego-headquartered biotechnology company develops photoimmunotherapy treatments for cancer patients.
Hisataka Kobayashi
He is the researcher who discovered the therapeutic potential of light-activated cancer cell destruction at the National Cancer Institute.
The details
The Alluminox treatment functions by tagging cancer cells with a light-activated dye before applying red light to destroy them. Rakuten Medical utilizes a business model where it installs the treatment platform at hospitals for free and collects revenue through drug sales.
Timeline
2011: Hisataka Kobayashi discovered the therapeutic potential of photoimmunotherapy.
- 2026-10-26
The current status of the firm's expansion was reported.
2028: The company plans to submit clinical trial data to the FDA.
The Big Picture
This development represents a significant shift from localized treatment protocols toward broader oncology applications. The current trial expansion follows the scientific trajectory set by the National Cancer Institute's photoimmunotherapy research.
The potential approval of this therapy would introduce a new light-activated treatment option for patients with solid tumors. Increased clinical trial activity in the United States may provide additional access to experimental protocols for qualifying participants.
The takeaway
The company's expansion highlights the growing role of light-activated dyes in modern cancer treatment. Success in these trials could transition the therapy from a niche application for head and neck cancers to a broader standard for all solid tumors.
Further reading
For more news on local life sciences, see our coverage of Biotech.
Source note: This article includes information reported by Fortune.
Live Poll
Would you prefer a less invasive light-based cancer treatment over traditional surgery if offered one?
